Biohit Oyj - Managers' Transactions
Biohit Oyj - Managers' Transactions, August 22, 2017 at 1:55 pm local time (EEST)
Biohit Oyj has received the following notification.
Person subject to the notification requirement |
Name: |
Korpela, Semi |
|
Position: |
Chief Executive Officer |
|
|
|
Initial Notification |
|
Reference number: |
74370089ATTSNBXJVT29_20170822112601_8 |
|
|
|
Issuer |
Name: |
Biohit Oyj |
LEI: |
74370089ATTSNBXJVT29 |
|
|
|
Transaction details |
Transaction date: |
2017-08-17 |
Venue: |
NASDAQ HELSINKI LTD (XHEL) |
Nature of the transaction: |
Exercise (Rights, Put and Call Options) |
Further details: |
|
|
Linked to stock option programme |
|
Instrument: |
Financial Instrument Linked to a Share or a Debt Instrument |
ISIN: |
FI4000219324 |
|
Volume: |
32274 |
Unit price: |
3,16770 Euro |
|
Aggregated transactions |
Volume: |
32274 |
Volume weighted average price: |
3.16770 Euro |
|
|
|
Transaction details |
Transaction date: |
2017-08-17 |
Venue: |
NASDAQ HELSINKI LTD (XHEL) |
Nature of the transaction: |
Subscription |
Further details: |
|
|
Linked to stock option programme |
|
Instrument: |
Financial Instrument Linked to a Share or a Debt Instrument |
ISIN: |
FI4000219324 |
|
Volume: |
7726 |
Unit price: |
2,27660 Euro |
|
Aggregated transactions |
Volume: |
7726 |
Volume weighted average price: |
2.27660 Euro |
|
|
|
Transaction details |
Transaction date: |
2017-08-17 |
Venue: |
NASDAQ HELSINKI LTD (XHEL) |
Nature of the transaction: |
Disposal |
Further details: |
|
|
Linked to stock option programme |
|
Instrument: |
Financial Instrument Linked to a Share or a Debt Instrument |
ISIN: |
FI4000219324 |
|
Volume: |
7726 |
Unit price: |
0,00000 Euro |
|
Aggregated transactions |
Volume: |
7726 |
Volume weighted average price: |
0.00000 Euro |
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
|